Cost-Benefit Analysis of a Haemophilus Influenzae Type B Meningitis Prevention Programme in The Philippines

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.19, Iss.4, 2001-04, pp. : 391-400

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-Benefit Analysis of Haemophilus influenzae Type b Vaccination in Children in Spain

By Jiménez F.J.

PharmacoEconomics, Vol. 15, Iss. 1, 1999-01 ,pp. : 75-83

Adis International

Access to resources Recommend Favorite

A Pharmacy-Based Health Promotion Programme in Hypertension: Cost-Benefit Analysis

By Côté I.

PharmacoEconomics, Vol. 21, Iss. 6, 2003-01 ,pp. : 415-428

Adis International

Access to resources Recommend Favorite

Cost-Benefit Analysis of Amtolmetin-Guacil

By Belisari A. Mantovani L.G.

Clinical Drug Investigation, Vol. 21, Iss. 1, 2001-01 ,pp. : 47-58

Adis International

Access to resources Recommend Favorite

An introduction to cost-effectiveness and cost–benefit analysis of pharmacogenomics

By Phillips Kathryn A Veenstra David Bebber Stephanie Van Sakowski Julie

Pharmacogenomics, Vol. 4, Iss. 3, 2003-05 ,pp. : 231-239

Future Medicine

Access to resources Recommend Favorite

Vaccination responses to Neisseria meningitidis and Haemophilus influenzae type b in two C2-deficient sisters

By Selander B. Kayhty H. Wedege E. Holmstrom E. Truedsson L. Soderstrom C. Sjoholm A.G.

Immunopharmacology, Vol. 49, Iss. 1, 2000-08 ,pp. : 74-74

Elsevier

Access to resources Recommend Favorite